Search

Displaying results 2361 - 2370 of 4590 in total
  1. Drug

    MM-093

    go.drugbank.com/drugs/DB05512
    Investigational

    MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults

  2. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    [A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual

  3. Drug

    AK119

    go.drugbank.com/drugs/DB16423
    Investigational

    AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).

  4. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.

  5. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    [A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.[L48827]

  6. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1. … [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.

  7. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542] … [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

  8. Drug

    Nadroparin

    go.drugbank.com/drugs/DB08813
    ApprovedInvestigationalWithdrawn

    Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa.

  9. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the

  10. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Asia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S. … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].